4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0002034671-25-000003
Chief Executive Officer sold 24,734 shares at an average $18.88 ($466,936)
- Chief Executive Officer acquired 24,734 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire Chief Executive Officer | 2025-10-13 | Option exercise 10b5-1 | +11,445 | $3.79 | $43,374 | 321,337 | D |
| Mazumdar Claire Chief Executive Officer | 2025-10-13 | Sale 10b5-1 | −11,445 | $18.92 | $216,545 | 309,892 | D |
| Mazumdar Claire Chief Executive Officer | 2025-10-15 | Option exercise 10b5-1 | +13,289 | $3.79 | $50,363 | 323,181 | D |
| Mazumdar Claire Chief Executive Officer | 2025-10-15 | Sale 10b5-1 | −13,289 | $18.84 | $250,391 | 309,892 | D |
| Derivatives | |||||||
| Mazumdar Claire Chief Executive Officer | 2025-10-13 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,445 | 314,662 | D | ||
| Mazumdar Claire Chief Executive Officer | 2025-10-15 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −13,289 | 301,373 | D | ||
| Open-market sales · 24,734 sh · avg $18.88 · $466,936 | |||||||
Loading xslF345X05/wk-form4_1760565614.xml…